Abstract:The present invention reveals a strong correlation between FGL-2 prothrombinase activity levels and the presence of a malignant proliferative disorder in a subject. Thus, the present invention provides FGL-2 prothrombinase activity as a diagnostic tool for malignancy.
Filed:July 11, 2011
Issued:May 5, 2015
Assignees:Mor Research Applications Ltd., Ramot at Tel-Aviv University Ltd.